When was AskBio founded?

AskBio was founded in 2001 and raised its 1st funding round 7 years after it was founded.

Where is AskBio located?

AskBio is headquartered in Durham, United States.

Who is the current CEO of AskBio?

Sheila Ann Mikhail of AskBio. They have also founded 1 company.

How many employees does AskBio have?

As of Aug 31, 2026, the latest employee count at AskBio is 509.

Is AskBio a funded company?

AskBio is a funded company, having raised a total of $235M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 26, 2008.

When was the latest funding round of AskBio?

AskBio's latest funding was a $***** Grant (prize money) round on Sep 02, 2020, with participation from 1 investor.

Where does AskBio rank among its competitors?

AskBio ranks 30th amongst 3342 active competitors, of which 1142 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of AskBio?

AskBio's top competitors include Jazz Pharmaceuticals, Ginkgo Bioworks and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

AskBio - 2026 Company Profile, Team, Funding & Competitors

Q: Is AskBio an acquired company?

AskBio got acquired by Bayer on Oct 26, 2020.

AskBio is an acquired company based in Durham (United States), founded in 2001 by Jude Samulski and Sheila Ann Mikhail. It operates as a Developer of AAV technologies for treating genetic and complex disorders. AskBio has raised $235M in funding from TPG and Vida Ventures. The company has 3342 active competitors, including 1142 funded and 813 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Ginkgo Bioworks and Biogen.

Company Details

Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.

Website: www.askbio.com/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2001

Location

Durham, United States

Stage

Acquired

Total Funding

$235M in 8 rounds

Latest Funding Round

Grant (prize money), Sep 02, 2020, $*****

Investors

TPG & 5 more

Ranked

30^th among 3342 active competitors

Employee Count

509 as on Aug 31, 2026

Investment & Acquisitions

Brain Vectis & 1 more

Similar Companies

Jazz Pharmaceuticals & 953 more

Exit Details

Acquired by Bayer (Oct 26, 2020)

View AskBio's full profile

AskBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SYNPROMICS LTD CIN: 1739278 , United States, Active		$1M - $5M (As on May 15, 2018)	-	-

AskBio got acquired by Bayer on Oct 26, 2020 at an acquisition amount of $*****.

Click here to take a look at AskBio's acquisition in detail

AskBio has raised a total funding of $235M over 8 rounds. Its first funding round was on Sep 26, 2008. Its latest funding round was a Grant (prize money) round on Sep 02, 2020 for $*****. 1 investor participated in its latest round. AskBio has 6 institutional investors.

Here is the list of recent funding rounds of AskBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2020	4636998	Grant (prize money)	7037093	8894775	6894613	3010750
Apr 11, 2019	5577680	PE	3068936	8657437	6098278	5906036
Aug 15, 2014	6335139	Grant (prize money)	2077964	1420309	8677530	HHS

Access funding benchmarks and valuations. Sign up today!

View details of AskBio's funding rounds and investors

The founders of AskBio are Jude Samulski and Sheila Ann Mikhail. Sheila Ann Mikhail is the CEO of AskBio.

Here are the details of AskBio's key team members:

Jude Samulski: Co-Founder & CSO of AskBio.
Contact Info: 1 email address
Sheila Ann Mikhail: Co-Founder & CEO of AskBio.

View details of AskBio's Founder profiles and Board Members

AskBio's employee count trend

AskBio has 509 employees as of Aug 26. Here is AskBio's employee count trend over the years:

Uncover AskBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AskBio include Jazz Pharmaceuticals, Ginkgo Bioworks and Biogen. Here is the list of Top 10 competitors of AskBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
7th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
10th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
30th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Columbus Venture Partners, Vida Ventures & 4 others	68/100